Efficacy and Safety of Endostar® Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas

  • Zhang, Lu-Ping (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Liao, Xing-Yun (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Xu, Yan-Mei (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Yan, Lv-Jun (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Yan, Gui-Fang (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Wang, Xin-Xin (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Duan, Yu-Zhong (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University) ;
  • Sun, Jian-Guo (Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University)
  • 발행 : 2013.07.30


Background: Soft tissue sarcomas (STS) are a heterogeneous group of tumors, and approximately 40-50% of patients with STS develop metastatic disease. The median overall survival of those patients was 12 months and their 5-year survival rate was 8%. Therefore, study on more effective treatment, especially the targeting therapies, is urgently needed. Objective: To evaluate the efficacy and safety of Endostar$^{(R)}$ combined with chemotherapy in patients with advanced STS. Methods: A retrospective case-series study was conducted in Cancer Institute of PLA, Xinqiao Hospital. A total of 71 patients suffering from advanced STS (IIB - IV) were included, of whom 49 cases treated with chemotherapy alone were defined as the control group and the rest 22 cases treated with the traditional chemotherapy combined with Endostar$^{(R)}$ were defined as the test group. The short-term therapeutic effects including objective response rate (ORR), disease control rate (DCR) and safety were evaluated in the two groups. In the follow-up, progression-free survival (PFS) and overall survival (OS) were also observed. Results: In the test and control groups, the ORR was 18.2% and 12.2%, respectively (P=0.767), and the DCR was 86.4% and 61.2%, respectively (P=0.034). The median time to progression in the test and control groups was 120 days and 70 days with significant difference (P = 0.017), while the median overall survival was 452 days and 286 days without significant difference (P=0.503). The one-year survival rate in the test group and control group was 56.2% and 35.4%, respectively, while the two-year survival rate was 30.2% and 26.5%, respectively. No significant difference in the side effects was found between the two groups. Conclusions: Endostar$^{(R)}$ combined with chemotherapy resulted in a higher DCR and longer PFS in the patients with advanced STS, and the toxicity was tolerable.


  1. Blay JY, Le CA, Cassier PA, et al (2012). Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov Med, 13, 357-67.
  2. Brand TM, Iida M, Wheeler DL (2011). Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther, 11, 777-92.
  3. Cen L, Hsieh FC, Lin HJ, et al (2007). PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer, 97, 785-91.
  4. Cohen MH, Johnson JR, Chattopadhyay S, et al (2010). Approval summary: erlotinib maintenance therapy of advanced/ metastatic non-small cell lung cancer (NSCLC). Oncologist, 15, 1344-51.
  5. Cormier JN, Pollock RE (2004). Soft tissue sarcomas. CA Cancer J Clin, 54, 94-109.
  6. Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 29, 15-8.
  7. Heudel P, Cassier P, Derbel O, et al (2012). Pazopanib for the treatment of soft-tissue sarcoma. Clin Pharmacol, 4, 65-70.
  8. Italiano A, Mathoulin-Pelissier S, Cesne AL, et al (2011). Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer, 117, 1049-54.
  9. Jia Y, Liu M, Huang W, et al (2012). Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol Oncol Res, 18, 315-23.
  10. Jiang LP, Zou C, Yuan X, et al (2009). N-terminal modification increases the stability of the recombinant human endostatin in vitro. Biotechnol Appl Biochem, 54, 113-20.
  11. Judson I (2010). Targeted therapies in soft tissue sarcomas. Ann Oncol, 21, vii277-80.
  12. Kaya M, Wada T, Nagoya S, et al (2007). Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci, 12, 562-7.
  13. Ke QH, Zhou SQ, Huang M, et al (2012). Early efficacy of Endostar combined with chemoradiotherapy for advanced cervical cancers. Asian Pac J Cancer Prev, 13, 923-26.
  14. Li Y, Huang XE, Yan PW, et al (2010). Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Asian Pac J Cancer Prev, 11, 1119-23.
  15. Olsson AK, Johansson I, Akerud H, et al (2004). The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Res, 64, 9012-17.
  16. Purohit S, Bhise R, Appachu S, et al (2011). Systemic therapy in soft tissue sarcomas: past, present and future. Indian J Surg Oncol, 2, 327-31.
  17. Reichardt P, Reichardt A, Pink D (2011). Molecular targeted therapy of gastrointestinal stromal tumors. Curr Cancer Drug Targets, 11, 688-97.
  18. Riedel RF (2012). Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. Cancer, 118, 1474-85.
  19. Sasaki T, Janne PA (2011). New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res, 17, 7213-18.
  20. Shukla NK, Deo SV (2011). Soft tissue sarcoma-review of experience at a tertiary care cancer centre. Indian J Surg Oncol, 2, 309-12.
  21. Tsukagoshi S (2010). [Introductory remarks of the 9th International Conference of the Asian Clinical Oncology Society (ACOS) Congress--Talk to the World Wide from Asia]. Gan To Kagaku Ryoho, 37, 2021-23.
  22. Vincenzi B, Napolitano A, D Onofrio L, et al (2011). Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. Expert Opin Investig Drugs, 20, 1685-705.
  23. Wang J, Sun Y, Liu Y, et al (2005). [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi, 8, 283-90.

피인용 문헌

  1. Computed Tomography Manifestations of Histologic Subtypes of Retroperitoneal Liposarcoma vol.15, pp.15, 2014,
  2. Anti-Tumor Effect of a Novel Soluble Recombinant Human Endostatin: Administered as a Single Agent or in Combination with Chemotherapy Agents in Mouse Tumor Models vol.9, pp.9, 2014,
  3. New Therapeutic Schedule for Prostatic Cancer-3 Cells with ET-1 RNAi and Endostar vol.15, pp.23, 2015,
  4. Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors vol.97, pp.45, 2018,